These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14531784)

  • 21. Critical Governance Issue of Parathyroid Hormone Assays and its Selection in the Management of Chronic Kidney Disease Mineral and Bone Disorders.
    Kakuta T; Ishida M; Fukagawa M
    Ther Apher Dial; 2018 Jun; 22(3):220-228. PubMed ID: 29781225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.
    Gal-Moscovici A; Popovtzer MM
    Clin Nephrol; 2005 Apr; 63(4):284-9. PubMed ID: 15847255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need for reliable serum parathyroid hormone measurements.
    Torres PU
    Kidney Int; 2006 Jul; 70(2):240-3. PubMed ID: 16838038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study.
    De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L
    Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Whole PTH and 1-84/84 PTH ratio for the non invasive determination of low bone turnover in renal osteodysthrophy].
    Negri AL; Alvarez Quiroga M; Bravo M; Fradinger E; Jacobo de Marino A; Bogado CE; Zanchetta JR
    Nefrologia; 2003; 23(4):327-32. PubMed ID: 14558332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolution of assays for parathyroid hormone.
    Goodman WG
    Semin Dial; 2005; 18(4):296-301. PubMed ID: 16076352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.
    Martin KJ; Jüppner H; Sherrard DJ; Goodman WG; Kaplan MR; Nassar G; Campbell P; Curzi M; Charytan C; McCary LC; Guo MD; Turner SA; Bushinsky DA
    Kidney Int; 2005 Sep; 68(3):1236-43. PubMed ID: 16105056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of 1-84 and intact parathyroid hormone assay in pediatric dialysis patients.
    Sheth RD; Goldstein SL
    Pediatr Nephrol; 2005 Jul; 20(7):977-81. PubMed ID: 15856315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients.
    Fehr T; Garzoni D; Staub T; Binet I; Wüthrich RP
    Kidney Blood Press Res; 2006; 29(3):175-81. PubMed ID: 16931896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients.
    Coen G; Ballanti P; Bonucci E; Calabria S; Centorrino M; Fassino V; Manni M; Mantella D; Mazzaferro S; Napoletano I; Sardella D; Taggi F
    Nephrol Dial Transplant; 1998 Sep; 13(9):2294-302. PubMed ID: 9761512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.
    Salusky IB; Ramirez JA; Oppenheim W; Gales B; Segre GV; Goodman WG
    Kidney Int; 1994 Jan; 45(1):253-8. PubMed ID: 8127016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum phosphorus adds to value of serum parathyroid hormone for assessment of bone turnover in renal osteodystrophy.
    Gentry J; Webb J; Davenport D; Malluche HH
    Clin Nephrol; 2016 Jul; 86(7):9-17. PubMed ID: 27191663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTH(1-84)/PTH(7-84): a balance of power.
    Friedman PA; Goodman WG
    Am J Physiol Renal Physiol; 2006 May; 290(5):F975-84. PubMed ID: 16601298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching between parathormone (PTH) assays: the impact on the diagnosis of renal osteodystrophy.
    Bekő G; Butz H; Berta K; Tislér A; Olajos F; Vásárhelyi B; Patócs A
    Clin Chem Lab Med; 2013 Jun; 51(6):1251-6. PubMed ID: 23241601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expectation for Whole PTH assay in the dialysis field].
    Tokumoto A
    Clin Calcium; 2005 Feb; 15(2):273-80. PubMed ID: 15692169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between a second and a third generation parathyroid hormone assay in hemodialysis patients.
    Gannagé-Yared MH; Farès C; Ibrahim T; Rahal ZA; Elias M; Chelala D
    Metabolism; 2013 Oct; 62(10):1416-22. PubMed ID: 23769129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parathyroid hormone measurement in chronic kidney disease: Impact of inter-method variability on mineral bone disease assessment.
    White CA; Sarabia S; Collier CP; McCudden C; Holden RM
    Clin Biochem; 2021 Aug; 94():62-66. PubMed ID: 33895125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.